[1]王承霞,朱玉蓉.乳腺癌患者血清中 tRF-32-Q99P9P9NH57SJ的表达及临床意义[J].现代检验医学杂志,2019,34(06):16-19.[doi:10.3969 ／ j.issn.1671-7414.2019.06.004]
　WANG Cheng-xia,ZHU Yu-rong.Expression and Clinical Significance of tRF-32-Q99P9P9NH57SJ in Serum of Patients with Breast Cancer[J].Journal of Modern Laboratory Medicine,2019,34(06):16-19.[doi:10.3969 ／ j.issn.1671-7414.2019.06.004]
点击复制

乳腺癌患者血清中 tRF-32-Q99P9P9NH57SJ的表达及临床意义()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第34卷
期数:
2019年06期
页码:
16-19
栏目:
论著
出版日期:
2019-12-30

文章信息/Info

Title:
Expression and Clinical Significance of tRF-32-Q99P9P9NH57SJ in Serum of Patients with Breast Cancer
文章编号:
1671-7414（2019）06-016-04
作者:
王承霞; 朱玉蓉
（江苏省肿瘤医院& 江苏省肿瘤防治研究所& 南京医科大学附属肿瘤医院检验科，南京　210009）
Author(s):
WANG Cheng-xia; ZHU Yu-rong
（Department of Clinical Laboratory, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & the Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009, China）
关键词:
乳腺癌; tRF-32-Q99P9P9NH57SJ; 荧光定量PCR; 临床诊断
分类号:
R737.9；R730.43
DOI:
10.3969 ／ j.issn.1671-7414.2019.06.004
文献标志码:
A
摘要:
目的　检测tRNA 及其来源片段（tRNA-derived fragments）- tRF-32-Q99P9P9NH57SJ（tRF-32）在乳腺癌患者 血清中的表达及意义。方法　选取2017 年11 月~ 2019 年2 月在江苏省肿瘤医院乳腺外科确诊的51 例乳腺癌患者及同 期25 例健康对照者的血清，记录患者临床资料。运用RT-PCR 检测血清tRF-32 的表达水平，分析其表达水平与临床病 理资料的关系。结果　51 例乳腺癌患者血清中tRF-32 的表达量（13.84 ± 2.62）与25 例健康对照组血清中的tRF-32 表 达量（39.47 ± 7.21）比较，差异有统计学意义（t = 4.091, P < 0.000 1）。临床TNM 分期I-II 期的tRF-32 表达量（16.97 ± 3.315）明显高于 III-IV 期tRF-32 表达量（7.07 ± 2.83），差异有统计学意义（t = 2.241, P = 0.029）。无淋巴结转移 患者血清中的tRF-32 表达量 (18.75 ± 3.91) 明显高于有淋巴结转移患者血清中tRF-32 表达量（7.80 ± 2.51)，差异有统 计学意义（t = 2.47, P = 0.017）。乳腺癌患者tRF-32 表达量与年龄无关（χ2=0.621，P >0.05），与TNM 临床分期（χ2=8.463, P = 0.004）以及淋巴结是否转移相关（χ2 =5.856, P = 0.016）。受试者工作曲线（receiver operating characteristic curve, ROC）显示血清tRF-32 诊断乳腺癌的曲线下面积（area under curve, AUC）是0.776（95% CI: 0.673 ~ 0.880），敏感度 和特异度分别为84.0 % 和68.8%。结论　tRF-32 在乳腺癌患者血清中低表达，tRF-32 的表达水平与乳腺癌的临床分期 和淋巴结转移有关。
Abstract:
Objective　To investigate the expression and significance of tRF-32 in breast cancer serum. Methods　The serum samples were collected form 51 patients with breast cancer in Jiangsu Cancer Hospital from November 2017 and February 2019, at the same time serum form 25 healthy controls were collected. The clinical data of patients were recorded. The expression level of tRF-32 was detected by RT-PCR, and analyzed its relationship with clinicopathologic factor of patients with breast cancer. Results　The serum level of tRF-32 in 51 patients with breast cancer (13.84 ± 2.62) was different form that in 25 healthy control group (39.47 ± 7.21) and they had statistical difference (t = 4.091, P < 0.000 1). Serum tRF-32 in patients with breast cancer was significantly difference between TNM stage I-II and stage III-IV (t = 2.241, P = 0.029). Meanwhile, the expression of tRF-32 in patients without lymph node metastasis was higher than those with lymph node metastasis (t = 2.47, P = 0.017). The level of serum tRF-32 was no correlated with ages (χ2=0.621，P >0.05). While there were significant association with TNM stage (χ2 =8.463, P = 0.004) and lymph node metastasis (χ2 =5.856, P = 0.016). Finally, the ROC-AUC for tRF-32 was 0.776 (95% CI: 0.673 ~0.880) for differentiating breast cancer patients from healthy controls, with a sensitivity of 84.0% and specificity of 68.8%. Conclusion tRF-32 was lower expression in patient’s serum with breast cancer. The expression level of tRF-32 was related to the clinical stage and lymph node metastasis of breast cancer.

参考文献/References:

[1]　CHEN Wanqing, ZHENG Rongshou, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA: A Cancer Journal for Clinicians, 2016, 66(2):115-132.
[2]　OLTMANN J, HESELMEYER-HADDAD K, HERNANDEZ L S, et al. Aneuploidy, TP53 mutation, and amplification of MYC correlate with increased intratumor heterogeneity and poor prognosis of breast cancer patients[J]. Genes, Chromosomes & Cancer, 2018, 57(4):165-175.
[3]　SIEGEL R L, MILLER K D, JEMAL A. Cancer Statistics, 2017[J]. CA: A Cancer Journal for Clinicians 2017, 67(1):7-30.
[4]　PIVOT X, COX D G: A new era for treatment development in HER2-positive breast cancer[J]. The Lancet Oncology, 2018, 19(2):160-162.
[5]　JANNING M, MULLER V, VETTORAZZI E, et al. Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: a biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial[J]. International Journal of Cancer, 2019, 45(3):857-868.
[6]　POMPON J, GARCIA-BLANCO M A. RNA: jack of all trades and master of all[J]. Cell, 2015, 160(4):579- 580.
[7]　LI Siqi, XU Zhengping, SHENG Jinghao. tRNA-derived small RNA: A novel regulatory small non-coding RNA[J]. Genes, 2018, 9(5):246.
[8]　ROMANO G, VENEZIANO D, ACUNZO M, et al. Small non-coding RNA and cancer[J]. Carcinogenesis, 2017, 38(5):485-491.
[9]　ELKORDY A, MISHIMA E, NIIZUMA K, et al. Stressinduced tRNA cleavage and tiRNA generation in rat neuronal PC12 cells[J]. Journal of Neurochemistry, 2018, 146(5):560-569.
[10] HUANG Shiqiong, SUN Bao, XIONG Zongping, et al.The dysregulation of tRNAs and tRNA derivatives in cancer[J]. Journal of Experimental & Clinical Cancer Research, 2018, 37(1):101.
[11] SHAO Yang, SUN Qiangling, LIU Xiaomin, et al. tRFLeu- CAG promotes cell proliferation and cell cycle in non-small cell lung cancer[J]. Chemical Biology & Drug design, 2017, 90(5):730-738.
[12] ZHOU Kun, DIEBEL K W, HOLY J, et al. A tRNA fragment, tRF5-Glu, regulates BCAR3 expression and proliferation in ovarian cancer cells[J]. Oncotarget, 2017, 8(56):95377-95391.
[13] GOODARZI H, LIU Xuhang, NGUYEN H C, et al. Endogenous tRNA-derived fragments suppress breast cancer progression via YBX1 displacement[J]. Cell, 2015, 161(4):790-802.
[14] DHAHBI J M, SPINDLER S R, ATAMNA H, et al. Deep sequencing of serum small RNAs identifies patterns of 5’ trna half and YRNA fragment expression associated with breast cancer[J]. Biomarkers in cancer, 2014, 6:37-47.
[15] COSENTINO C, TOIVONEN S, DIAZ VILLAMIL E, et al. Pancreatic beta-cell tRNA hypomethylation and fragmentation link TRMT10A deficiency with diabetes[J]. Nucleic Acids Research, 2018, 46(19):10302-10318.
[16] SUN Chunxiao, YANG Fan, ZHANG Yanhong, et al. tRNA-derived fragments as novel predictive biomarkers for trastuzumab-resistant breast cancer[J]. Cellular Physiology and Biochemistry, 2018, 49(2):419-431.
[17] GOGAKOS T, BROWN M, GARZIA A, et al. Characterizing expression and processing of precursor and mature human tRNAs by Hydro-tRNAseq and PARCLIP[ J]. Cell Reports, 2017, 20(6):1463-1475.

相似文献/References:

[1]党小军,张华,王欣.人附睾蛋白4(HE4)在乳腺癌诊断中的价值[J].现代检验医学杂志,2015,30(06):84.[doi:10.3969/j.issn.1671-7414.2015.06.024]
　DANG Xiao-jun,ZHANG Hua,WANG Xin.Value of Human Epididymis Protein 4(HE4) in Diagnosis of Breast Cancer[J].Journal of Modern Laboratory Medicine,2015,30(06):84.[doi:10.3969/j.issn.1671-7414.2015.06.024]
[2]张 萍,任世云,张 雷.乳腺癌患者血清脂质运载蛋白-2 和基质金属蛋白酶-9的表达及临床意义[J].现代检验医学杂志,2015,30(01):72.[doi:10.3969/j.issn.1671-7414.2015.01.019]
　ZHANG Ping,REN Shi-yun,ZHANG Lei.Expression and Clinical Significance of Serum LCN-2 and MMP-9 in Patients with Breast Cancer[J].Journal of Modern Laboratory Medicine,2015,30(06):72.[doi:10.3969/j.issn.1671-7414.2015.01.019]
[3]乔雪峰a,黄志平b,张 宁c,等.IL-18基因启动子区-137G/C,-607G/T 2个位点基因多态性与女性乳腺癌易感性Meta分析[J].现代检验医学杂志,2016,31(04):65.[doi:10.3969/j.issn.16717-414.2016.04.017]
　QIAO Xue-fenga,HUANG Zhi-pingb,ZHANG Ningc,et al.Association Analysis of IL-18 Gene Promoter Region -137G/C,-607G/T Polymorphisms and Susceptibility to Sporadic Breast Cancer:Meta-Analysis[J].Journal of Modern Laboratory Medicine,2016,31(06):65.[doi:10.3969/j.issn.16717-414.2016.04.017]
[4]刘延梅,马少君,张月浪,等.人类表皮生长因子受体2在乳腺癌表达与临床的相关病理特征分析[J].现代检验医学杂志,2016,31(05):91.[doi:10.3969/j.issn.1671-7414.2016.05.024]
　LIU Yan-mei,MA Shao-jun,ZHANG Yue-lang,et al.Expression of Human Epidermal Growth Factor Receptor 2 and Correlation with Clinical Pathological Features in Breast Cancer[J].Journal of Modern Laboratory Medicine,2016,31(06):91.[doi:10.3969/j.issn.1671-7414.2016.05.024]
[5]陈雨欣,谭婷婷,宁明哲.乳腺癌患者血清中白介素35(IL-35)的表达及其临床意义[J].现代检验医学杂志,2017,32(02):92.[doi:10.3969/j.issn.1671-7414.2017.02.025]
　CHEN Yu-xin,TAN Ting-ting,NING Ming-zhe.Serological Interleukin-35 Level in Patients with Breast Cancer and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2017,32(06):92.[doi:10.3969/j.issn.1671-7414.2017.02.025]
[6]唐努尔·艾尔肯,阿孜古·祖农.盐酸罗哌卡因对人乳腺癌细胞运动作用的研究[J].现代检验医学杂志,2017,32(03):128.[doi:10.3969/j.issn.1671-7414.2017.03.035]
　TANGNUER·Aierken,AZIGU·Zunong.Study on Effect of Ropivacaine on Migration of Breast Cancer Cell s[J].Journal of Modern Laboratory Medicine,2017,32(06):128.[doi:10.3969/j.issn.1671-7414.2017.03.035]
[7]靳庆娥,苏建荣.北京地区汉族女性人群SYK基因启动子区-803A>Trs290987单核苷酸多态性与乳腺癌易感性分析[J].现代检验医学杂志,2018,33(02):5.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　JIN Qing-e,SU Jian-rong.Associations of SYK Promoter-803A >T(rs290987)Single Nucleotide Polymorphisms with Susceptibility to Breast Cancer of Han Female Population in Beijing Area[J].Journal of Modern Laboratory Medicine,2018,33(06):5.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[8]高 华a,李玉柱b,韩龙才c,等.Logistic回归和ROC工作曲线评价联合检测血清CA153,TPS,CYFRA21-1在乳腺癌诊断中的临床价值[J].现代检验医学杂志,2018,33(03):60.[doi:10.3969/j.issn.1671-7414.2018.03.016]
　GAO Huaa,LI Yu-zhub,HAN Long-caic,et al.Clinical Value of Logistic Regression and ROC Work Curve Evaluating Serum CA153,TPS and Cyfra21-1 for Diagnosis of Breast Cancer[J].Journal of Modern Laboratory Medicine,2018,33(06):60.[doi:10.3969/j.issn.1671-7414.2018.03.016]
[9]李 娜a,赵晓娟b,苏晓明a.乳腺组织中SMG-1mRNA和SOX4mRNA检测在乳腺癌监测中的应用[J].现代检验医学杂志,2019,34(02):35.[doi:10.3969/j.issn.1671-7414.2019.02.010]
　LI Naa,ZHAO Xiao-juanb,SU Xiao-minga.Application of Detection of SMG-1mRNA and SOX4mRNAin Breast Tissue in Surveillance for Breast Cancer[J].Journal of Modern Laboratory Medicine,2019,34(06):35.[doi:10.3969/j.issn.1671-7414.2019.02.010]
[10]王 碧,吉茂礼.乳腺癌组织长链非编码RNA UCA1和BCAR4表达与辅助化疗效果的相关性研究[J].现代检验医学杂志,2019,34(05):77.[doi:10.3969/j.issn.1671-7414.2019.05.019]
　WANG Bi,JI Mao-li.Correlational Research on the Expressionof Long-Chain Non-Coding RNA UCA1 and BCAR4in Breast Cancer Tissues for the Effect of Adjuvant Chemotherapy[J].Journal of Modern Laboratory Medicine,2019,34(06):77.[doi:10.3969/j.issn.1671-7414.2019.05.019]

备注/Memo

备注/Memo:
作者简介：王承霞（1973- ）女，本科，主管技师，主要研究方向为肿瘤分子诊断，E-mail:newwcx@163.com。收稿日期：2019-09-05
更新日期/Last Update: 2019-12-25